The primary objective of this meta-analysis was the comparison of the time to first occurrence of confirmed four-component major adverse cardiovascular events including cardiovascular death, myocardial infarction, stroke and hospitalized unstable angina between tirzepatide groups and control groups
At our practice, we strive to provide the best possible care for our clients in their journey to weight loss
They are not a magic solution weight loss still comes down to burning more calories than you consume
Meanwhile, in a broader population study, including individuals without established cardiovascular disease, dulaglutide reduced major adverse cardiovascular events by 12 percent
Takeaways: The peptide known as Retatrutide, scientifically referred to as LY3437943, is currently undergoing stage three clinical trials under the auspices of the FDA and is developed by Eli Lilly
A malignant melanotic tumour of ganglion cells arising from a thoracic sympathetic ganglion